|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benson AB, Bekaii-Saab T, Chan E, Chen YJ,
Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ,
et al: National Comprehensive Cancer Network: Localized colon
cancer, version 3.2013: Featured updates to the NCCN Guidelines. J
Natl Compr Canc Netw. 11:519–528. 2013.PubMed/NCBI
|
|
3
|
Pritchard CC and Grady WM: Colorectal
cancer molecular biology moves into clinical practice. Gut.
60:116–129. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Winder T and Lenz HJ: Molecular predictive
and prognostic markers in colon cancer. Cancer Treat Rev.
36:550–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vanhoefer U, Harstrick A, Achterrath W,
Cao S, Seeber S and Rustum YM: Irinotecan in the treatment of
colorectal cancer: Clinical overview. J Clin Oncol. 19:1501–1518.
2001.PubMed/NCBI
|
|
6
|
Xu Y and Villalona-Calero MA: Irinotecan:
Mechanisms of tumor resistance and novel strategies for modulating
its activity. Ann Oncol. 13:1841–1851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Allen WL, Coyle VM and Johnston PG:
Predicting the outcome of chemotherapy for colorectal cancer. Curr
Opin Pharmacol. 6:332–336. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leslie EM, Deeley RG and Cole SP:
Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2,
and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol.
204:216–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han B and Zhang JT: Multidrug resistance
in cancer chemotherapy and xenobiotic protection mediated by the
half ATP-binding cassette transporter ABCG2. Curr Med Chem
Anticancer Agents. 4:31–42. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benderra Z, Faussat AM, Sayada L, Perrot
JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP and Legrand O:
MRP3, BCRP, and P-glycoprotein activities are prognostic factors in
adult acute myeloid leukemia. Clin Cancer Res. 11:7764–7772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burger H, Foekens JA, Look MP, Meijer-van
Gelder ME, Klijn JG, Wiemer EA, Stoter G and Nooter K: RNA
expression of breast cancer resistance protein, lung
resistance-related protein, multidrug resistance-associated
proteins 1 and 2, and multidrug resistance gene 1 in breast cancer:
Correlation with chemotherapeutic response. Clin Cancer Res.
9:827–836. 2003.PubMed/NCBI
|
|
12
|
Friedrich RE, Punke C and Reymann A:
Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in
primary oral squamous cell carcinoma. In Vivo. 18:133–147.
2004.PubMed/NCBI
|
|
13
|
Tsunoda S, Okumura T, Ito T, Kondo K,
Ortiz C, Tanaka E, Watanabe G, Itami A, Sakai Y and Shimada Y:
ABCG2 expression is an independent unfavorable prognostic factor in
esophageal squamous cell carcinoma. Oncology. 71:251–258. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim YH, Ishii G, Goto K, Ota S, Kubota K,
Murata Y, Mishima M, Saijo N, Nishiwaki Y and Ochiai A: Expression
of breast cancer resistance protein is associated with a poor
clinical outcome in patients with small-cell lung cancer. Lung
Cancer. 65:105–111. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Robey RW, To KK, Polgar O, Dohse M, Fetsch
P, Dean M and Bates SE: ABCG2: A perspective. Adv Drug Deliv Rev.
61:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gupta N, Martin PM, Miyauchi S, Ananth S,
Herdman AV, Martindale RG, Podolsky R and Ganapathy V:
Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.
Biochem Biophys Res Commun. 343:571–577. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Candeil L, Gourdier I, Peyron D, Vezzio N,
Copois V, Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, et
al: ABCG2 overexpression in colon cancer cells resistant to SN-38
and in irinotecan-treated metastases. Int J Cancer. 109:848–854.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Muro K, Boku N, Shimada Y, Tsuji A,
Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, et al:
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid
plus irinotecan (FOLFIRI) as second-line chemotherapy for
metastatic colorectal cancer: A randomised phase 2/3
non-inferiority study (FIRIS study). Lancet Oncol. 11:853–860.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kobayashi H: Development of a new in vitro
chemosensitivity test using collagen gel droplet embedded culture
and image analysis for clinical usefulness. Recent Results Cancer
Res. 161:48–61. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
22
|
Hosmer DW and Lemeshow S: Applied Logistic
Regression. Shewhart WA and Wilks SS: 2nd. John Wiley & Sons,
Inc.; New York: pp. 31–46. 2000
|
|
23
|
Kawabata S, Oka M, Shiozawa K, Tsukamoto
K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y,
et al: Breast cancer resistance protein directly confers SN-38
resistance of lung cancer cells. Biochem Biophys Res Commun.
280:1216–1223. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Robey RW, Ierano C, Zhan Z and Bates SE:
The challenge of exploiting ABCG2 in the clinic. Curr Pharm
Biotechnol. 12:595–608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mo W and Zhang JT: Human ABCG2: Structure,
function and its role in multidrug resistance. Int J Biochem Mol
Biol. 3:1–27. 2012.PubMed/NCBI
|
|
26
|
Dietrich CG, Vehr AK, Martin IV, Gassler
N, Rath T, Roeb E, Schmitt J, Trautwein C and Geier A:
Downregulation of breast cancer resistance protein in colon
adenomas reduces cellular xenobiotic resistance and leads to
accumulation of a food-derived carcinogen. Int J Cancer.
129:546–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Glasgow SC, Yu J, Carvalho LP, Shannon WD,
Fleshman JW and McLeod HL: Unfavourable expression of pharmacologic
markers in mucinous colorectal cancer. Br J Cancer. 92:259–264.
2005.PubMed/NCBI
|
|
28
|
Xiang L, Su P, Xia S, Liu Z, Wang Y, Gao P
and Zhou G: ABCG2 is associated with HER-2 expression, lymph node
metastasis and clinical stage in breast invasive ductal carcinoma.
Diagn Pathol. 6:902011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin Y, Bin ZQ, Qiang H, Liang C, Hua C,
Jun D, Dong WA and Qing L: ABCG2 is related with the grade of
glioma and resistance to mitoxantone, a chemotherapeutic drug for
glioma. J Cancer Res Clin Oncol. 135:1369–1376. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gongora C, VezzioVie N, Tuduri S, Denis V,
Causse A, Auzanneau C, CollodBeroud G, Coquelle A, Pasero P,
Pourquier P, et al: New Topoisomerase I mutations are associated
with resistance to camptothecin. Mol Cancer. 10:642011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
DelRio M, Molina F, BascoulMollevi C,
Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N,
Fraslon C, et al: Gene expression signature in advanced colorectal
cancer patients select drugs and response for the use of
leucovorin, fluorouracil, and irinotecan. J Clin Oncol. 25:773–780.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lansiaux A, BrasGoncalves RA, Rosty C,
LaurentPuig P, Poupon MF and Bailly C: Topoisomerase I-DNA covalent
complexes in human colorectal cancer xenografts with different p53
and microsatellite instability status: Relation with their
sensitivity to CTP-11. Anticancer Res. 21:471–476. 2001.PubMed/NCBI
|
|
33
|
Paradiso A, Xu J, Mangia A, Chiriatti A,
Simone G, Zito A, Montemurro S, Giuliani F, Maiello E and Colucci
G: Topoisomerase-I, thymidylate synthase primary tumour expression
and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced
colorectal cancer patients. Int J Cancer. 111:252–258. 2004.
View Article : Google Scholar : PubMed/NCBI
|
